lactic acid has been researched along with Pancreatic Neoplasms in 79 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Resistance to gemcitabine remains a key challenge in the treatment of pancreatic ductal adenocarcinoma (PDAC), necessitating the constant search for effective strategies for a priori prediction of clinical outcome." | 7.88 | Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine. ( Alkaff, SMF; Chan, CY; Chan, ECY; Goh, S; Kam, JH; Leow, WQ; Lim, TKH; Phua, LC; Tai, DWM, 2018) |
| " In order to enhance the biological activity of α-mangostin, we formulated mangostin-encapsulated PLGA nanoparticles (Mang-NPs) and examined the molecular mechanisms by which they inhibit human and KC mice (Pdx(Cre);LSL-Kras(G12D)) pancreatic CSC characteristics in vitro, and pancreatic carcinogenesis in KPC (Pdx(Cre);LSLKras(G12D);LSL-Trp53(R172H)) mice." | 7.83 | α-Mangostin-encapsulated PLGA nanoparticles inhibit pancreatic carcinogenesis by targeting cancer stem cells in human, and transgenic (Kras(G12D), and Kras(G12D)/tp53R270H) mice. ( Shankar, S; Shrivastava, A; Srivastava, RK; Verma, RK; Yu, W, 2016) |
| " However, due to its minimal water solubility, it is necessary to prepare an optimal nano-sized vehicle to overcome the low bioavailability issue." | 5.72 | Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells. ( Gubernator, J; Jaromin, A; Markowski, A; Migdał, P; Olczak, E; Pawlik, K; Zaremba-Czogalla, M; Zygmunt, A, 2022) |
| "Resistance to gemcitabine remains a key challenge in the treatment of pancreatic ductal adenocarcinoma (PDAC), necessitating the constant search for effective strategies for a priori prediction of clinical outcome." | 3.88 | Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine. ( Alkaff, SMF; Chan, CY; Chan, ECY; Goh, S; Kam, JH; Leow, WQ; Lim, TKH; Phua, LC; Tai, DWM, 2018) |
| " In order to enhance the biological activity of α-mangostin, we formulated mangostin-encapsulated PLGA nanoparticles (Mang-NPs) and examined the molecular mechanisms by which they inhibit human and KC mice (Pdx(Cre);LSL-Kras(G12D)) pancreatic CSC characteristics in vitro, and pancreatic carcinogenesis in KPC (Pdx(Cre);LSLKras(G12D);LSL-Trp53(R172H)) mice." | 3.83 | α-Mangostin-encapsulated PLGA nanoparticles inhibit pancreatic carcinogenesis by targeting cancer stem cells in human, and transgenic (Kras(G12D), and Kras(G12D)/tp53R270H) mice. ( Shankar, S; Shrivastava, A; Srivastava, RK; Verma, RK; Yu, W, 2016) |
| "Of the 20 patients, 17 patients had carcinoid tumors and three had islet cell tumors." | 2.69 | Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. ( Ajani, JA; Brown, CA; Carrasco, HC; Chuang, VP; Diamandidou, E; Lawrence, DD; Wallace, S; Yang, DJ, 1998) |
| "The MS analyses from pancreatic cancer cells support a hypothesis that hypoxia promotes cells in solid tumor to reprogram metabolic pathways in order to minimize the oxygen consumption." | 2.52 | Cancer metabolism and mass spectrometry-based proteomics. ( Liotta, LA; Petricoin, EF; Zhou, W, 2015) |
| " However, the in vivo experiments indicate that applying a higher dosage or using other drugs targeting these metabolic pathways might be more promising." | 1.72 | Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism. ( Goldstein, L; Joksch, M; Krause, B; Kumstel, S; Lindner, T; Schönrogge, M; Schreiber, T; Stenzel, J; Vollmar, B; Wendt, EHU; Zechner, D; Zhang, X, 2022) |
| " However, due to its minimal water solubility, it is necessary to prepare an optimal nano-sized vehicle to overcome the low bioavailability issue." | 1.72 | Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells. ( Gubernator, J; Jaromin, A; Markowski, A; Migdał, P; Olczak, E; Pawlik, K; Zaremba-Czogalla, M; Zygmunt, A, 2022) |
| "Leptin is an adipokine that is significantly increased in obese patients and that functions in various biological processes of cancer, such as tumor growth and metastasis." | 1.56 | Leptin receptor mediates the proliferation and glucose metabolism of pancreatic cancer cells via AKT pathway activation. ( Chen, J; Sheng, H; Tan, M; Tian, X; Xu, W; Xu, Y; Zhang, J, 2020) |
| "MUC1 may be a therapeutic target in pancreatic cancer treatment." | 1.56 | MUC1 promotes glycolysis through inhibiting BRCA1 expression in pancreatic cancer. ( Fu, X; Mao, L; Qiu, YD; Tang, N; Xie, WQ, 2020) |
| "Resected pancreatic cancer (n = 21) and normal pancreas were laser-capture micro-dissected, and transcripts were quantified by RNAseq." | 1.48 | Identification of a pyruvate-to-lactate signature in pancreatic intraductal papillary mucinous neoplasms. ( Bamlet, WR; Carlson, SK; Couch, FJ; Damgard, SE; Deelchand, DK; Kittelson, E; Marjańska, M; Murphy, SJ; O'Brien, DR; Passow, MR; Penheiter, AR; Port, JD; Smyrk, TC; Vasmatzis, G, 2018) |
| "Since pancreatic cancer is a hypovascular tumor with comparably insufficient energy supply, we further investigate the relationship between PKM2 and hypoglucose." | 1.48 | The responsively decreased PKM2 facilitates the survival of pancreatic cancer cells in hypoglucose. ( Chen, J; Deng, S; He, C; Jin, Y; Li, X; Liu, M; Qin, Q; Wang, C; Zhao, G; Zhu, S, 2018) |
| " However, low aqueous solubility, poor stability and decreased bioavailability associated with native curcumin holds back its use in clinical settings." | 1.48 | Evaluation of curcumin loaded chitosan/PEG blended PLGA nanoparticles for effective treatment of pancreatic cancer. ( Arya, G; Das, M; Sahoo, SK, 2018) |
| "Metabolic changes induced by pancreatic cancer were investigated by 1H NMR spectroscopy of plasma samples of patients and healthy controls." | 1.48 | Diagnosis of pancreatic cancer via ( Habartová, L; Horník, Š; Michálková, L; Setnička, V; Sýkora, J, 2018) |
| " In all groups, no adverse effects were noted, and all animals showed favorable local and systemic tolerability." | 1.43 | Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy. ( Domb, AJ; Gabai, RM; Marzoli, GA; Muravnik, S; Nyska, A; Ramot, Y; Rotkopf, S; Shemi, A; Zorde Khvalevsky, E, 2016) |
| "Pancreatic cancer is the fourth leading cancer with 85% mortality rate in USA alone and it is prevalent in many other developed and developing countries." | 1.42 | Gemcitabine loaded biodegradable PLGA nanospheres for in vitro pancreatic cancer therapy. ( Jaidev, LR; Krishnan, UM; Sethuraman, S, 2015) |
| "BxPC-3 pancreatic cancer cells were cultured under hypoxic conditions and treated with or without the nanoparticles." | 1.42 | PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo. ( Fang, W; Li, K; Li, L; Pan, X; Sun, Y; Zhao, Z; Zhu, Q; Zhu, Y; Zuo, J, 2015) |
| "Pancreatic cancer is the fourth most prevalent cancer with about an 85% mortality rate; thus, an utmost need exists to discover new therapeutic modalities that would enhance therapy outcomes of this disease with minimal or no side effects." | 1.42 | Nanoparticle formulation of ormeloxifene for pancreatic cancer. ( Balabathula, P; Balakrishna, S; Behrman, SW; Chauhan, N; Chauhan, SC; Ebeling, MC; Ellis, RT; Halaweish, FT; Jaggi, M; Khan, S; Singh, MM; Thompson, PA; Yallapu, MM; Zafar, N, 2015) |
| "Thiamine exhibited a lower IC50 value in both cell lines compared with DCA." | 1.40 | High-dose vitamin B1 reduces proliferation in cancer cell lines analogous to dichloroacetate. ( Berger, R; Hanberry, BS; Zastre, JA, 2014) |
| "The K-ras mutation in pancreatic cancer can inhibit drug delivery and increase drug resistance." | 1.40 | Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer. ( Abril, ER; Guzman, R; Jeffery, JJ; Lucero-Acuña, A; Meuillet, EJ; Nagle, RB; Pagel, MD, 2014) |
| " A method was developed to simulate the dosing rate and cumulative dose released in the peritoneal cavity based on the in vitro release data." | 1.39 | Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics. ( Au, JL; Lu, Z; Tsai, M; Wientjes, MG, 2013) |
| "IP glycerol was only moderately indicative for ischemia after 91-120 minutes with 0,791 ROC AUCs (threshold 122 μmol/l)." | 1.39 | Validation of intraluminal and intraperitoneal microdialysis in ischemic small intestine. ( Minkkinen, M; Nordback, I; Perner, A; Pynnönen, L; Räty, S; Sand, J; Tenhunen, J, 2013) |
| "Gemcitabine was encapsulated in two types of commonly used nanovectors, namely poly(lactic-co-glycolic acid) (PLGA) and cholesterol-based liposomes, and their physico-chemical parameters assessed in vitro." | 1.38 | Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells. ( Banerjee, D; Basu, S; Harfouche, R; Papa, AL; Sengupta, P; Sengupta, S, 2012) |
| "Pancreatic cancer is a malignant tumor with the worst prognosis among all cancers." | 1.37 | Metabolomic profiling of serum from human pancreatic cancer patients using 1H NMR spectroscopy and principal component analysis. ( Chen, Z; Huang, H; OuYang, D; Xu, J, 2011) |
| "The role of CD147 in pancreatic cancer, however, remains elusive." | 1.35 | CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. ( Adler, G; Bucholz, M; Gress, TM; Gschwend, JE; Holzmann, KH; Marx, M; Oswald, F; Scheler, M; Schneiderhan, W; Seufferlein, T, 2009) |
| "Additionally, the lipid content in pancreatic cancer was higher than that in chronic pancreatitis." | 1.34 | Discrimination of metabolic profiles of pancreatic cancer from chronic pancreatitis by high-resolution magic angle spinning 1H nuclear magnetic resonance and principal components analysis. ( Chen, Q; Deng, H; Fang, F; He, X; Lu, J; Spraul, M; Yu, Y, 2007) |
| "Our findings demonstrate that pancreatic cancer cell conditioned media enhanced lactate production and induced proteolysis, possibly by altering expression levels of a large number of genes, not only those involved in protein biosynthesis and degradation or glucose metabolism, but also those involved in the tricarboxylic acid cycle and in vesicle traffic." | 1.32 | Altered glucose metabolism and proteolysis in pancreatic cancer cell conditioned myoblasts: searching for a gene expression pattern with a microarray analysis of 5000 skeletal muscle genes. ( Avogaro, A; Basso, D; Bellin, M; Dussini, N; Fogar, P; Greco, E; Lanfranchi, G; Millino, C; Navaglia, F; Pedrazzoli, S; Plebani, M; Romualdi, C; Valerio, A; Zambon, CF, 2004) |
| "Sera was obtained from patients with pancreatic cancer ( n = 14) and chronic pancreatitis ( n = 9) and healthy control subjects ( n = 10)." | 1.31 | Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide. ( Basso, D; Fogar, P; Gallo, N; Greco, E; Mazza, S; Pedrazzoli, S; Piva, MG; Plebani, M; Seraglia, R; Tiengo, A; Valerio, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.80) | 18.7374 |
| 1990's | 9 (11.39) | 18.2507 |
| 2000's | 7 (8.86) | 29.6817 |
| 2010's | 43 (54.43) | 24.3611 |
| 2020's | 17 (21.52) | 2.80 |
| Authors | Studies |
|---|---|
| Kumstel, S | 1 |
| Schreiber, T | 1 |
| Goldstein, L | 1 |
| Stenzel, J | 1 |
| Lindner, T | 1 |
| Joksch, M | 1 |
| Zhang, X | 1 |
| Wendt, EHU | 2 |
| Schönrogge, M | 1 |
| Krause, B | 1 |
| Vollmar, B | 2 |
| Zechner, D | 2 |
| Kong, X | 1 |
| Feng, M | 1 |
| Wu, L | 1 |
| He, Y | 1 |
| Mao, H | 1 |
| Gu, Z | 1 |
| Markowski, A | 1 |
| Jaromin, A | 1 |
| Migdał, P | 1 |
| Olczak, E | 1 |
| Zygmunt, A | 1 |
| Zaremba-Czogalla, M | 1 |
| Pawlik, K | 1 |
| Gubernator, J | 1 |
| Ge, W | 1 |
| Meng, L | 1 |
| Cao, S | 1 |
| Hou, C | 1 |
| Zhu, X | 1 |
| Huang, D | 1 |
| Li, Q | 1 |
| Peng, Y | 1 |
| Jiang, K | 1 |
| Silva, A | 1 |
| Cerqueira, MC | 1 |
| Rosa, B | 1 |
| Sobral, C | 1 |
| Pinto-Ribeiro, F | 1 |
| Costa, MF | 1 |
| Baltazar, F | 1 |
| Afonso, J | 1 |
| Kitamura, F | 1 |
| Semba, T | 1 |
| Yasuda-Yoshihara, N | 1 |
| Yamada, K | 1 |
| Nishimura, A | 1 |
| Yamasaki, J | 1 |
| Nagano, O | 1 |
| Yasuda, T | 1 |
| Yonemura, A | 1 |
| Tong, Y | 1 |
| Wang, H | 1 |
| Akiyama, T | 1 |
| Matsumura, K | 1 |
| Uemura, N | 1 |
| Itoyama, R | 1 |
| Bu, L | 1 |
| Fu, L | 1 |
| Hu, X | 1 |
| Wei, F | 1 |
| Mima, K | 1 |
| Imai, K | 1 |
| Hayashi, H | 1 |
| Yamashita, YI | 1 |
| Miyamoto, Y | 1 |
| Baba, H | 1 |
| Ishimoto, T | 1 |
| Montrazi, ET | 1 |
| Sasson, K | 2 |
| Agemy, L | 2 |
| Peters, DC | 1 |
| Brenner, O | 1 |
| Scherz, A | 2 |
| Frydman, L | 2 |
| Bhagat, TD | 1 |
| Von Ahrens, D | 1 |
| Dawlaty, M | 1 |
| Zou, Y | 1 |
| Baddour, J | 1 |
| Achreja, A | 1 |
| Zhao, H | 1 |
| Yang, L | 1 |
| Patel, B | 1 |
| Kwak, C | 1 |
| Choudhary, GS | 1 |
| Gordon-Mitchell, S | 1 |
| Aluri, S | 1 |
| Bhattacharyya, S | 1 |
| Sahu, S | 1 |
| Bhagat, P | 1 |
| Yu, Y | 2 |
| Bartenstein, M | 1 |
| Giricz, O | 1 |
| Suzuki, M | 1 |
| Sohal, D | 1 |
| Gupta, S | 2 |
| Guerrero, PA | 1 |
| Batra, S | 1 |
| Goggins, M | 1 |
| Steidl, U | 1 |
| Greally, J | 1 |
| Agarwal, B | 1 |
| Pradhan, K | 1 |
| Banerjee, D | 2 |
| Nagrath, D | 1 |
| Maitra, A | 2 |
| Verma, A | 1 |
| Xu, Y | 1 |
| Tan, M | 1 |
| Tian, X | 1 |
| Zhang, J | 3 |
| Chen, J | 2 |
| Xu, W | 1 |
| Sheng, H | 1 |
| Schoenrogge, M | 1 |
| Fu, X | 1 |
| Tang, N | 1 |
| Xie, WQ | 1 |
| Mao, L | 1 |
| Qiu, YD | 1 |
| Krapf, SA | 1 |
| Lund, J | 1 |
| Lundkvist, M | 1 |
| Dale, MG | 1 |
| Nyman, TA | 1 |
| Thoresen, GH | 1 |
| Kase, ET | 1 |
| Ma, M | 1 |
| Ma, C | 2 |
| Li, P | 1 |
| Ping, F | 1 |
| Li, W | 1 |
| Xu, L | 1 |
| Zhang, H | 1 |
| Sun, Q | 1 |
| Li, Y | 1 |
| Yang, X | 1 |
| Lu, Y | 1 |
| Hang, J | 1 |
| Zhang, T | 1 |
| Huo, Y | 1 |
| Liu, J | 1 |
| Lai, S | 1 |
| Luo, D | 1 |
| Wang, L | 1 |
| Hua, R | 1 |
| Lin, Y | 1 |
| Kesh, K | 1 |
| Garrido, VT | 1 |
| Dosch, A | 1 |
| Durden, B | 1 |
| Gupta, VK | 1 |
| Sharma, NS | 1 |
| Lyle, M | 1 |
| Nagathihalli, N | 1 |
| Merchant, N | 1 |
| Saluja, A | 1 |
| Banerjee, S | 1 |
| Donisi, G | 1 |
| Barbagallo, M | 1 |
| Capretti, G | 1 |
| Nappo, G | 1 |
| Takis, PG | 1 |
| Zerbi, A | 1 |
| Marchesi, F | 1 |
| Cortese, N | 1 |
| Cui, J | 1 |
| Guo, Y | 1 |
| Wu, H | 1 |
| Xiong, J | 1 |
| Peng, T | 1 |
| Markovic, S | 1 |
| Roussel, T | 1 |
| Preise, D | 1 |
| Dovmark, TH | 1 |
| Saccomano, M | 1 |
| Hulikova, A | 1 |
| Alves, F | 1 |
| Swietach, P | 1 |
| Hui, S | 1 |
| Ghergurovich, JM | 1 |
| Morscher, RJ | 1 |
| Jang, C | 1 |
| Teng, X | 1 |
| Lu, W | 1 |
| Esparza, LA | 1 |
| Reya, T | 1 |
| Yanxiang Guo, J | 1 |
| White, E | 1 |
| Rabinowitz, JD | 1 |
| Penheiter, AR | 1 |
| Deelchand, DK | 1 |
| Kittelson, E | 1 |
| Damgard, SE | 1 |
| Murphy, SJ | 1 |
| O'Brien, DR | 1 |
| Bamlet, WR | 1 |
| Passow, MR | 1 |
| Smyrk, TC | 1 |
| Couch, FJ | 1 |
| Vasmatzis, G | 1 |
| Port, JD | 1 |
| Marjańska, M | 1 |
| Carlson, SK | 1 |
| Phua, LC | 1 |
| Goh, S | 1 |
| Tai, DWM | 1 |
| Leow, WQ | 1 |
| Alkaff, SMF | 1 |
| Chan, CY | 1 |
| Kam, JH | 1 |
| Lim, TKH | 1 |
| Chan, ECY | 1 |
| Li, X | 2 |
| Deng, S | 2 |
| Liu, M | 1 |
| Jin, Y | 1 |
| Zhu, S | 1 |
| He, C | 1 |
| Qin, Q | 1 |
| Wang, C | 1 |
| Zhao, G | 1 |
| Arya, G | 1 |
| Das, M | 1 |
| Sahoo, SK | 1 |
| Daman, Z | 1 |
| Faghihi, H | 1 |
| Montazeri, H | 1 |
| Fujioka, R | 1 |
| Mochizuki, N | 1 |
| Ikeda, M | 1 |
| Sato, A | 1 |
| Nomura, S | 1 |
| Owada, S | 1 |
| Yomoda, S | 1 |
| Tsuchihara, K | 1 |
| Kishino, S | 1 |
| Esumi, H | 1 |
| Michálková, L | 1 |
| Horník, Š | 1 |
| Sýkora, J | 1 |
| Habartová, L | 1 |
| Setnička, V | 1 |
| Lee, Y | 1 |
| Kang, Y | 2 |
| Dai, B | 1 |
| Perez, MR | 2 |
| Pratt, M | 2 |
| Koay, EJ | 2 |
| Kim, M | 2 |
| Brekken, RA | 1 |
| Fleming, JB | 2 |
| Dutta, P | 1 |
| Lee, J | 1 |
| Salzillo, TC | 1 |
| Weygand, J | 1 |
| Zacharias, NM | 1 |
| Gammon, ST | 1 |
| McAllister, F | 1 |
| Sen, S | 1 |
| Piwnica-Worms, D | 1 |
| Bhattacharya, PK | 1 |
| Silva, C | 1 |
| Correia-Branco, A | 1 |
| Andrade, N | 1 |
| Ferreira, AC | 1 |
| Soares, ML | 1 |
| Sonveaux, P | 1 |
| Stephenne, J | 1 |
| Martel, F | 1 |
| Guillaumond, F | 1 |
| Leca, J | 1 |
| Olivares, O | 1 |
| Lavaut, MN | 1 |
| Vidal, N | 1 |
| Berthezène, P | 1 |
| Dusetti, NJ | 1 |
| Loncle, C | 1 |
| Calvo, E | 1 |
| Turrini, O | 1 |
| Iovanna, JL | 1 |
| Tomasini, R | 1 |
| Vasseur, S | 1 |
| Longati, P | 1 |
| Jia, X | 1 |
| Eimer, J | 1 |
| Wagman, A | 1 |
| Witt, MR | 1 |
| Rehnmark, S | 1 |
| Verbeke, C | 1 |
| Toftgård, R | 1 |
| Löhr, M | 1 |
| Heuchel, RL | 1 |
| Ota, S | 1 |
| Geschwind, JF | 1 |
| Buijs, M | 1 |
| Wijlemans, JW | 1 |
| Kwak, BK | 1 |
| Ganapathy-Kanniappan, S | 1 |
| Tsai, M | 1 |
| Lu, Z | 1 |
| Wientjes, MG | 1 |
| Au, JL | 1 |
| Zhou, W | 1 |
| Liotta, LA | 1 |
| Petricoin, EF | 1 |
| Park, K | 1 |
| Pynnönen, L | 1 |
| Minkkinen, M | 1 |
| Perner, A | 1 |
| Räty, S | 1 |
| Nordback, I | 1 |
| Sand, J | 1 |
| Tenhunen, J | 1 |
| Hanberry, BS | 1 |
| Berger, R | 1 |
| Zastre, JA | 1 |
| Frasco, MF | 1 |
| Almeida, GM | 1 |
| Santos-Silva, F | 1 |
| Pereira, Mdo C | 1 |
| Coelho, MA | 1 |
| Jaidev, LR | 1 |
| Krishnan, UM | 1 |
| Sethuraman, S | 1 |
| Lucero-Acuña, A | 1 |
| Jeffery, JJ | 1 |
| Abril, ER | 1 |
| Nagle, RB | 1 |
| Guzman, R | 1 |
| Pagel, MD | 2 |
| Meuillet, EJ | 2 |
| Byeon, HJ | 1 |
| Kim, I | 1 |
| Choi, JS | 1 |
| Lee, ES | 1 |
| Shin, BS | 1 |
| Youn, YS | 1 |
| Pan, X | 1 |
| Zhu, Q | 1 |
| Sun, Y | 1 |
| Li, L | 2 |
| Zhu, Y | 1 |
| Zhao, Z | 1 |
| Zuo, J | 1 |
| Fang, W | 1 |
| Li, K | 1 |
| Malm, SW | 1 |
| Hanke, NT | 1 |
| Gill, A | 1 |
| Carbajal, L | 1 |
| Baker, AF | 1 |
| Khan, S | 1 |
| Chauhan, N | 1 |
| Yallapu, MM | 1 |
| Ebeling, MC | 1 |
| Balakrishna, S | 1 |
| Ellis, RT | 1 |
| Thompson, PA | 1 |
| Balabathula, P | 1 |
| Behrman, SW | 1 |
| Zafar, N | 1 |
| Singh, MM | 1 |
| Halaweish, FT | 1 |
| Jaggi, M | 1 |
| Chauhan, SC | 1 |
| Tao, Z | 1 |
| Cheng, M | 1 |
| Hu, H | 1 |
| Wang, S | 1 |
| Su, J | 1 |
| Lv, W | 1 |
| Guo, H | 1 |
| Tang, J | 1 |
| Cao, B | 1 |
| Shukla, SK | 1 |
| Gunda, V | 1 |
| Abrego, J | 1 |
| Haridas, D | 1 |
| Mishra, A | 1 |
| Souchek, J | 1 |
| Chaika, NV | 1 |
| Yu, F | 1 |
| Sasson, AR | 1 |
| Lazenby, AJ | 1 |
| Batra, SK | 1 |
| Singh, PK | 1 |
| Verma, RK | 2 |
| Yu, W | 2 |
| Singh, SP | 1 |
| Shankar, S | 2 |
| Srivastava, RK | 2 |
| Jiang, Y | 1 |
| Wu, GH | 1 |
| He, GD | 1 |
| Zhuang, QL | 1 |
| Xi, QL | 1 |
| Zhang, B | 1 |
| Han, YS | 1 |
| Fang, J | 1 |
| Kobes, JE | 1 |
| Daryaei, I | 1 |
| Howison, CM | 1 |
| Bontrager, JG | 1 |
| Sirianni, RW | 1 |
| Allen, E | 1 |
| Miéville, P | 1 |
| Warren, CM | 1 |
| Saghafinia, S | 1 |
| Peng, MW | 1 |
| Hanahan, D | 1 |
| Ramot, Y | 1 |
| Rotkopf, S | 1 |
| Gabai, RM | 1 |
| Zorde Khvalevsky, E | 1 |
| Muravnik, S | 1 |
| Marzoli, GA | 1 |
| Domb, AJ | 1 |
| Shemi, A | 1 |
| Nyska, A | 1 |
| Lü, JM | 1 |
| Liang, Z | 1 |
| Wang, X | 1 |
| Gu, J | 1 |
| Yao, Q | 1 |
| Chen, C | 1 |
| Shrivastava, A | 1 |
| Sudha, T | 1 |
| Bharali, DJ | 1 |
| Yalcin, M | 1 |
| Darwish, NH | 1 |
| Debreli Coskun, M | 1 |
| Keating, KA | 1 |
| Lin, HY | 1 |
| Davis, PJ | 1 |
| Mousa, SA | 1 |
| Schneiderhan, W | 1 |
| Scheler, M | 1 |
| Holzmann, KH | 1 |
| Marx, M | 1 |
| Gschwend, JE | 1 |
| Bucholz, M | 1 |
| Gress, TM | 1 |
| Seufferlein, T | 1 |
| Adler, G | 1 |
| Oswald, F | 1 |
| Aggarwal, S | 1 |
| Yadav, S | 1 |
| OuYang, D | 1 |
| Xu, J | 1 |
| Huang, H | 1 |
| Chen, Z | 1 |
| Tesiram, YA | 1 |
| Lerner, M | 1 |
| Stewart, C | 1 |
| Njoku, C | 1 |
| Brackett, DJ | 1 |
| Zhang, L | 1 |
| Jin, H | 1 |
| Guo, X | 1 |
| Yang, Z | 1 |
| Zhao, L | 1 |
| Tang, S | 1 |
| Mo, P | 1 |
| Wu, K | 1 |
| Nie, Y | 1 |
| Pan, Y | 1 |
| Fan, D | 1 |
| Papa, AL | 1 |
| Basu, S | 1 |
| Sengupta, P | 1 |
| Sengupta, S | 1 |
| Harfouche, R | 1 |
| Basso, D | 4 |
| Millino, C | 1 |
| Greco, E | 2 |
| Romualdi, C | 1 |
| Fogar, P | 2 |
| Valerio, A | 4 |
| Bellin, M | 1 |
| Zambon, CF | 1 |
| Navaglia, F | 1 |
| Dussini, N | 1 |
| Avogaro, A | 2 |
| Pedrazzoli, S | 2 |
| Lanfranchi, G | 1 |
| Plebani, M | 4 |
| Maher, JC | 1 |
| Savaraj, N | 1 |
| Priebe, W | 1 |
| Liu, H | 1 |
| Lampidis, TJ | 1 |
| Fang, F | 1 |
| He, X | 1 |
| Deng, H | 1 |
| Chen, Q | 1 |
| Lu, J | 1 |
| Spraul, M | 1 |
| Yeo, TK | 1 |
| Kintner, J | 1 |
| Armand, R | 1 |
| Perez, R | 1 |
| Lewis, LD | 1 |
| Brigato, L | 2 |
| Panozzo, MP | 1 |
| Miola, M | 1 |
| Lucca, T | 1 |
| Ujka, F | 1 |
| Zaninotto, M | 1 |
| Diamandidou, E | 1 |
| Ajani, JA | 1 |
| Yang, DJ | 1 |
| Chuang, VP | 1 |
| Brown, CA | 1 |
| Carrasco, HC | 1 |
| Lawrence, DD | 1 |
| Wallace, S | 1 |
| Wang, F | 1 |
| Larsson, J | 1 |
| Adrian, TE | 2 |
| Gasslander, T | 1 |
| Permert, J | 1 |
| Ceolotto, G | 1 |
| Baldo, G | 1 |
| Tiengo, A | 2 |
| Akiyoshi, H | 1 |
| Iwamoto, M | 1 |
| Nakaya, Y | 1 |
| Li, J | 1 |
| Petrowsky, H | 1 |
| Heinrich, S | 1 |
| Janshon, G | 1 |
| Staib-Sebler, E | 1 |
| Poloczek, Y | 1 |
| Gog, C | 1 |
| Oremek, G | 1 |
| Lorenz, M | 1 |
| Ladriere, L | 1 |
| Kadiata, MM | 1 |
| Verbruggen, I | 1 |
| Willem, R | 1 |
| Malaisse, WJ | 3 |
| Seraglia, R | 1 |
| Mazza, S | 1 |
| Piva, MG | 1 |
| Gallo, N | 1 |
| Best, L | 2 |
| Trebilcock, R | 2 |
| Tomlinson, S | 2 |
| Lynch, A | 1 |
| Hale, PJ | 1 |
| Nattrass, M | 1 |
| Sener, A | 2 |
| Blachier, F | 1 |
| Giroix, MH | 1 |
| Dufrane, SP | 1 |
| Malaisse-Lagae, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX[NCT03450018] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2019-01-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for lactic acid and Pancreatic Neoplasms
| Article | Year |
|---|---|
Prognostic Value of Monocarboxylate Transporter 1 Overexpression in Cancer: A Systematic Review.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lactic Acid; Lung Neoplasms; Monocarboxylic Acid Transporter | 2023 |
Cancer metabolism and mass spectrometry-based proteomics.
Topics: Animals; Cell Hypoxia; Glioblastoma; Glutamine; Glycolysis; Humans; Isoenzymes; L-Lactate Dehydrogen | 2015 |
2 trials available for lactic acid and Pancreatic Neoplasms
| Article | Year |
|---|---|
Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with gemcitabine-refractory pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Arctium; Area Under Curve; Biomarkers; Carcinoma, Adenosquamous; | 2018 |
Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Capsules; Carcinoid Tumor; Chemoembolization, Therapeuti | 1998 |
75 other studies available for lactic acid and Pancreatic Neoplasms
| Article | Year |
|---|---|
Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism.
Topics: Animals; Caprylates; Cell Line, Tumor; Humans; Lactic Acid; Mice; Pancreatic Neoplasms; Positron Emi | 2022 |
Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism.
Topics: Animals; Caprylates; Cell Line, Tumor; Humans; Lactic Acid; Mice; Pancreatic Neoplasms; Positron Emi | 2022 |
Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism.
Topics: Animals; Caprylates; Cell Line, Tumor; Humans; Lactic Acid; Mice; Pancreatic Neoplasms; Positron Emi | 2022 |
Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism.
Topics: Animals; Caprylates; Cell Line, Tumor; Humans; Lactic Acid; Mice; Pancreatic Neoplasms; Positron Emi | 2022 |
Biodegradable gemcitabine-loaded microdevice with sustained local drug delivery and improved tumor recurrence inhibition abilities for postoperative pancreatic tumor treatment.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Lactic Acid; M | 2022 |
Biodegradable gemcitabine-loaded microdevice with sustained local drug delivery and improved tumor recurrence inhibition abilities for postoperative pancreatic tumor treatment.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Lactic Acid; M | 2022 |
Biodegradable gemcitabine-loaded microdevice with sustained local drug delivery and improved tumor recurrence inhibition abilities for postoperative pancreatic tumor treatment.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Lactic Acid; M | 2022 |
Biodegradable gemcitabine-loaded microdevice with sustained local drug delivery and improved tumor recurrence inhibition abilities for postoperative pancreatic tumor treatment.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Lactic Acid; M | 2022 |
Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells.
Topics: Adenocarcinoma; Humans; Lactic Acid; Liposomes; Nanoparticles; Pancreatic Neoplasms; Particle Size; | 2022 |
The SIX1/LDHA Axis Promotes Lactate Accumulation and Leads to NK Cell Dysfunction in Pancreatic Cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; | 2023 |
The SIX1/LDHA Axis Promotes Lactate Accumulation and Leads to NK Cell Dysfunction in Pancreatic Cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; | 2023 |
The SIX1/LDHA Axis Promotes Lactate Accumulation and Leads to NK Cell Dysfunction in Pancreatic Cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; | 2023 |
The SIX1/LDHA Axis Promotes Lactate Accumulation and Leads to NK Cell Dysfunction in Pancreatic Cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; | 2023 |
Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer.
Topics: Animals; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Glucose; Humans; Lactic Acid; | 2023 |
Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer.
Topics: Animals; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Glucose; Humans; Lactic Acid; | 2023 |
Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer.
Topics: Animals; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Glucose; Humans; Lactic Acid; | 2023 |
Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer.
Topics: Animals; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Glucose; Humans; Lactic Acid; | 2023 |
High-sensitivity deuterium metabolic MRI differentiates acute pancreatitis from pancreatic cancers in murine models.
Topics: Acute Disease; Animals; Deuterium; Disease Models, Animal; Humans; Lactic Acid; Magnetic Resonance I | 2023 |
Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts.
Topics: 5-Methylcytosine; Animals; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, T | 2019 |
Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts.
Topics: 5-Methylcytosine; Animals; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, T | 2019 |
Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts.
Topics: 5-Methylcytosine; Animals; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, T | 2019 |
Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts.
Topics: 5-Methylcytosine; Animals; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, T | 2019 |
Leptin receptor mediates the proliferation and glucose metabolism of pancreatic cancer cells via AKT pathway activation.
Topics: Cell Line, Tumor; Cell Proliferation; Chromones; Gene Silencing; Glucose; Glucose Transporter Type 1 | 2020 |
Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells.
Topics: Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, | 2020 |
MUC1 promotes glycolysis through inhibiting BRCA1 expression in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cell Line, Tumor; Cell Proli | 2020 |
Pancreatic cancer cells show lower oleic acid oxidation and their conditioned medium inhibits oleic acid oxidation in human myotubes.
Topics: Biological Transport; Cell Line, Tumor; Culture Media, Conditioned; Energy Metabolism; Epithelial Ce | 2020 |
Low glucose enhanced metformin's inhibitory effect on pancreatic cancer cells by suppressing glycolysis and inducing energy stress via up-regulation of miR-210-5p.
Topics: Anaerobiosis; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Energ | 2020 |
Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the Radioresistance of Pancreatic Cancer.
Topics: Animals; Disease Models, Animal; Humans; Immunosuppression Therapy; Lactic Acid; Mice; Myeloid-Deriv | 2020 |
Stroma secreted IL6 selects for "stem-like" population and alters pancreatic tumor microenvironment by reprogramming metabolic pathways.
Topics: AC133 Antigen; Animals; Cell Line, Tumor; Heterografts; Humans; Interleukin-6; Lactic Acid; Male; Me | 2020 |
Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Biomarkers, Tumor; Cell Line, Tumor; Extracellular Fluid; Glucose; Humans; | 2020 |
Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; | 2021 |
Deuterium MRSI characterizations of glucose metabolism in orthotopic pancreatic cancer mouse models.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deuterium; Disease Models, | 2021 |
Connexin-43 channels are a pathway for discharging lactate from glycolytic pancreatic ductal adenocarcinoma cells.
Topics: Acidosis, Lactic; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Connexin 43; Gap Junction | 2017 |
Glucose feeds the TCA cycle via circulating lactate.
Topics: Animals; Blood Glucose; Brain; Carbon; Citric Acid Cycle; Fasting; Glucose; Glutamine; Glycolysis; L | 2017 |
Identification of a pyruvate-to-lactate signature in pancreatic intraductal papillary mucinous neoplasms.
Topics: Adenocarcinoma, Mucinous; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Gen | 2018 |
Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Pancreatic Ductal; Deo | 2018 |
The responsively decreased PKM2 facilitates the survival of pancreatic cancer cells in hypoglucose.
Topics: Adenylate Kinase; Autophagy; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2018 |
Evaluation of curcumin loaded chitosan/PEG blended PLGA nanoparticles for effective treatment of pancreatic cancer.
Topics: Apoptosis; Cell Death; Cell Line, Tumor; Cell Movement; Cell Survival; Chitosan; Curcumin; Endocytos | 2018 |
Salinomycin nanoparticles interfere with tumor cell growth and the tumor microenvironment in an orthotopic model of pancreatic cancer.
Topics: Animals; Apoptosis; beta Catenin; Cadherins; Cell Line, Tumor; Cell Proliferation; Female; Humans; L | 2018 |
Diagnosis of pancreatic cancer via
Topics: 3-Hydroxybutyric Acid; Aged; Aged, 80 and over; Amino Acids; Biomarkers, Tumor; Blood; Female; Human | 2018 |
Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell | 2019 |
Combining Hyperpolarized Real-Time Metabolic Imaging and NMR Spectroscopy To Identify Metabolic Biomarkers in Pancreatic Cancer.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Glycolysis; Heterografts; Humans; Hypoxia- | 2019 |
Selective pro-apoptotic and antimigratory effects of polyphenol complex catechin:lysine 1:2 in breast, pancreatic and colorectal cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Biological Transport; Breast Neoplasms; Catechin; Cell Line, Tumor | 2019 |
Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Disease Models | 2013 |
3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Disease Models, Anim | 2013 |
Ultrasound-guided direct delivery of 3-bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic cancer.
Topics: Adenosine Triphosphate; Animals; Cell Death; Cell Line, Tumor; Female; Humans; Ki-67 Antigen; Lactic | 2013 |
Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Delayed-Action Preparations; Female; H | 2013 |
In vitro and in vivo correlation of paclitaxel-loaded polymeric microparticles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Delayed-Action Preparations; Female; Humans; Lactic Acid | 2013 |
Validation of intraluminal and intraperitoneal microdialysis in ischemic small intestine.
Topics: Aged; Carcinoma; Female; Glucose; Glycerol; Humans; Intestine, Small; Ischemia; Lactic Acid; Male; M | 2013 |
High-dose vitamin B1 reduces proliferation in cancer cell lines analogous to dichloroacetate.
Topics: Caspase 3; Cell Line, Tumor; Cell Proliferation; Dichloroacetic Acid; Glucose; Humans; Lactic Acid; | 2014 |
Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells.
Topics: Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Endocytosis; Humans; Lactic Acid; Nanoparti | 2015 |
Gemcitabine loaded biodegradable PLGA nanospheres for in vitro pancreatic cancer therapy.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; H | 2015 |
Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Female; Humans; Lactic Acid; Mice; | 2014 |
PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy.
Topics: Animals; Antineoplastic Agents; Lactic Acid; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microspher | 2015 |
PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo.
Topics: Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Cell Proliferati | 2015 |
The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines.
Topics: Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Dose-Respon | 2015 |
Nanoparticle formulation of ormeloxifene for pancreatic cancer.
Topics: Animals; Benzopyrans; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Female; Humans; Lactic Ac | 2015 |
Altered Plasticity of Glycogen Phosphorylase in Forebrain Gliosomes Obtained from Insulinoma Patients.
Topics: Adenosine Triphosphate; Aged; Astrocytes; Case-Control Studies; Cyclic AMP-Dependent Protein Kinases | 2015 |
MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism.
Topics: CA-125 Antigen; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Knockdown Techniques; Gluc | 2015 |
Anthothecol-encapsulated PLGA nanoparticles inhibit pancreatic cancer stem cell growth by modulating sonic hedgehog pathway.
Topics: Animals; Antimalarials; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Surv | 2015 |
The Effect of Silencing HIF-1α Gene in BxPC-3 Cell Line on Glycolysis-Related Gene Expression, Cell Growth, Invasion, and Apoptosis.
Topics: Animals; Apoptosis; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression; Gen | 2015 |
Improved Treatment of Pancreatic Cancer With Drug Delivery Nanoparticles Loaded With a Novel AKT/PDK1 Inhibitor.
Topics: Animals; Cell Line, Tumor; Lactic Acid; Mice; Nanoparticles; Pancreatic Neoplasms; Polyglycolic Acid | 2016 |
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling.
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expres | 2016 |
Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Drug Carriers; Lactic Acid; Pancreatic | 2016 |
New polymer of lactic-co-glycolic acid-modified polyethylenimine for nucleic acid delivery.
Topics: Animals; Cell Line, Tumor; Cell Survival; DNA; Female; Genetic Therapy; HEK293 Cells; Humans; Lactic | 2016 |
α-Mangostin-encapsulated PLGA nanoparticles inhibit pancreatic carcinogenesis by targeting cancer stem cells in human, and transgenic (Kras(G12D), and Kras(G12D)/tp53R270H) mice.
Topics: Animals; Antigens, CD; Apoptosis; Cadherins; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell S | 2016 |
Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug | 2017 |
CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models.
Topics: Animals; Basigin; Blotting, Western; Carcinoma, Pancreatic Ductal; Chick Embryo; Dose-Response Relat | 2009 |
EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer.
Topics: Antibodies, Monoclonal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Compounding; ErbB Recep | 2011 |
Metabolomic profiling of serum from human pancreatic cancer patients using 1H NMR spectroscopy and principal component analysis.
Topics: 3-Hydroxybutyric Acid; Aged; Female; Humans; Lactic Acid; Magnetic Resonance Spectroscopy; Male; Met | 2011 |
Utility of nuclear magnetic resonance spectroscopy for pancreatic cancer studies.
Topics: Biomarkers, Tumor; Blood Glucose; Case-Control Studies; Choline; Fatty Acids, Unsaturated; Female; H | 2012 |
Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by (1)H nuclear magnetic resonance-based metabonomic profiles.
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Aged; Aged, 80 and over; Amino Acids; Biomarkers, Tumor; C | 2012 |
Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cholesterol; Deoxycytidine; Gemcitabine; Humans; | 2012 |
Altered glucose metabolism and proteolysis in pancreatic cancer cell conditioned myoblasts: searching for a gene expression pattern with a microarray analysis of 5000 skeletal muscle genes.
Topics: Aged; Analysis of Variance; Animals; Cell Line, Tumor; Culture Media, Conditioned; Female; Gene Expr | 2004 |
Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression.
Topics: Antimetabolites; Biomarkers, Tumor; Cell Line, Tumor; Deoxyglucose; Drug Resistance, Neoplasm; Excit | 2005 |
Discrimination of metabolic profiles of pancreatic cancer from chronic pancreatitis by high-resolution magic angle spinning 1H nuclear magnetic resonance and principal components analysis.
Topics: Animals; Choline; Chronic Disease; Diagnosis, Differential; Disease Models, Animal; Lactic Acid; Lip | 2007 |
Sublethal concentrations of gemcitabine (2',2'-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Polymerase gamm | 2007 |
An unidentified pancreatic cancer cell product alters some intracellular pathways of glucose metabolism in isolated rat hepatocytes.
Topics: Animals; Culture Media, Conditioned; Glucose; Glycolysis; Humans; Insulin; Kinetics; Lactic Acid; Li | 1997 |
In vitro influences between pancreatic adenocarcinoma cells and pancreatic islets.
Topics: Adenocarcinoma; Animals; Cell Division; Coculture Techniques; Glucose; Humans; Insulin; Insulin Secr | 1998 |
Glucose metabolic alterations in isolated and perfused rat hepatocytes induced by pancreatic cancer conditioned medium: a low molecular weight factor possibly involved.
Topics: Animals; Biological Factors; Cell Membrane; Cells, Cultured; Culture Media, Conditioned; Cytosol; Di | 1999 |
Lactate stimulates insulin secretion without blocking the K+ channels in HIT-T15 insulinoma cells.
Topics: Adenosine Triphosphate; Animals; Calcium; Calcium Radioisotopes; Cricetinae; Cytosol; Electrophysiol | 1999 |
A factor from pancreatic and colonic cancer cells stimulates glucose uptake and lactate production in myoblasts.
Topics: Animals; Biological Factors; Cell Line; Colonic Neoplasms; Culture Media, Conditioned; Cycloheximide | 1999 |
[Technique and pathophysiology of isolated hypoxic perfusion of the abdomen].
Topics: Acid-Base Equilibrium; Aged; Antibiotics, Antineoplastic; Carbon Dioxide; Catheterization; Chemother | 1999 |
Metabolism of D-[1,2-13C]glucose and alpha-D-[1,2-13C]glucose pentaacetate in tumoral pancreatic islet cells.
Topics: Acetates; Adenoma, Islet Cell; Culture Media; Glucose; Humans; Lactic Acid; Pancreatic Neoplasms; Tu | 2000 |
Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide.
Topics: Adult; Aged; Animals; Cells, Cultured; Culture Media, Conditioned; Female; Glucose; Humans; Lactic A | 2002 |
Lactate transport in insulin-secreting beta-cells: contrast between rat islets and HIT-T15 insulinoma cells.
Topics: 4-Chloromercuribenzenesulfonate; Amiloride; Animals; Biological Transport; Carrier Proteins; Cells, | 1992 |
Na+/H+ exchange is responsible for intracellular pH regulation in insulin-secreting HIT-T15 cells.
Topics: 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; 4,4'-Diisothiocyanostilbene-2,2'-Disulfo | 1990 |
Metabolic profiles in patients with insulinoma.
Topics: Adenoma, Islet Cell; Adult; Aged; Alanine; Blood Glucose; Fatty Acids, Nonesterified; Female; Glycer | 1989 |
Crabtree effect in tumoral pancreatic islet cells.
Topics: Adenine Nucleotides; Adenoma, Islet Cell; Animals; Glucose; Glutamine; Lactates; Lactic Acid; Lipids | 1988 |
Environmental modulation of the anomeric specificity of glucose metabolism in normal and tumoral cells.
Topics: Animals; Cell Line; Erythrocytes; Glucose; Islets of Langerhans; Lactates; Lactic Acid; Leukemia, Ly | 1985 |